RxSight Reports Q2 2024 Financial Results
DENVER, Colo., Aug 06, 2024 (247marketnews.com)- RxSight, Inc. (NASDAQ: RXST) reported its second quarter 2024 financial results including a 68% year-over-year increase in second quarter 2024 revenue, to $34.9 million, and sales of 24,214 Light Adjustable Lenses, a 92% increase in procedure volume compared to the second quarter of 2023.
“In the second quarter, we continued to make significant progress in the adoption of adjustability as a new standard in the premium market, highlighted by robust LDD sales and the positive reception of the recently launched LAL+,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. “The ability to adjust the optical power of the lens after surgery is increasingly valued by both doctors and patients for the excellent clinical outcomes and personalized approach it enables. As we move forward, we remain dedicated to expanding our presence and driving innovation within the global premium IOL market.”
RxSight also increased its 2024 full-year revenue guidance to $139.0-140.0 million, an implied growth rate of 56% to 57% compared to 2023.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (RXST)
- RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance
- RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance
- RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance
- RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference